Results 41 to 50 of about 5,159 (158)

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

, 2021
Background: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations.
Burrows, Sally, Barrett, P Hugh R, Watts, Gerald F, Dent, Ricardo, Chan, Dick C, Scott, Rob, Somaratne, Ransi, Wasserman, Scott M   +7 more
core   +1 more source

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type‐9 inhibitor for intensive lipid‐lowering, on intracranial atherosclerotic stenosis.
Xinzhi Hu, Yiyang Liu, Weizhuang Yuan, Zongmuyu Zhang, Shun Li, Anqi Cheng, Qiuyu Yu, Haoyao Guo, Yinxi Zou, Mingli Li, Caiyan Liu, Yan Xu, Weihai Xu   +12 more
doaj   +1 more source

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol

Frontiers in Physiology, 2021
Background: Several studies have demonstrated that using a higher dose of statin can easily induce liver injury and myopathy. Low-density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor for cardiovascular disease; however ...
Jing Gao, Jing Gao, Jing-Yu Liu, Peng-Ju Lu, Jian-Yong Xiao, Ming-Dong Gao, Chang-Ping Li, Zhuang Cui, Yin Liu, Yin Liu   +9 more
doaj   +1 more source

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety [PDF]

, 2019
We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open-label, parallel-design study in participants with normal renal ...
Sreeneeranj Kasichayanula, Scott M. Wasserman, Ogo Egbuna, Kasichayanula, Sreeneeranj, Egbuna, Ogo, Emery, Maurice, Maurice G. Emery, Patrick Hanafin, Gibbs, John, Lee, Edward, Wasserman, Scott, Geoffrey Block, Edward Lee, Hanafin, Patrick, John P. Gibbs, Ransi Somaratne, Hamilton, Lisa, Somaratne, Ransi, Lisa Hamilton, Block, Geoffrey   +19 more
core   +1 more source

Isolated Gamma‐Glutamyltransferase Elevation During Statin Therapy: A Diagnostic Pitfall and a Stepwise Management Framework to Prevent Unnecessary Discontinuation

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT The management of patients with isolated gamma‐glutamyltransferase (GGT) elevation during statin therapy remains a common clinical dilemma due to the unclear relevance to hepatotoxicity. We report a case of a patient with coronary artery disease who developed persistent isolated GGT elevation (> 100 U/L) while on atorvastatin, with normal ...
Jun Yang, Yanling He, Zhengyong Zhang
wiley   +1 more source

Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Cardiology Research and Practice, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI).
Yu Ma, Lei Zha, Qi Zhang, Lu Cao, Ru Zhao, Jing Ma, Kai Hou, Yue Pan, Hongliang Cong, Ximing Li   +9 more
doaj   +1 more source

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

Cardiology and Therapy, 2023
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries.
Milan Gupta, Rajvi J. Wani, Khalid Al Faraidy, Jean Bergeron, Eduardo Contreras, Angel Alberto Garcia Peña, G. B. John Mancini, Francisco Padilla, Abel Alberto Pavia Lopez, Kiran Philip, Johnny Wu, Erin S. Mackinnon   +11 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, Volume 15, Issue 20, 27 May 2026.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Evolocumab: rising momentum as novel antidyslipidemic drug

, 2017
Increased levels of low density lipoprotein cholesterol are responsible for the major cardiovascular events. Low density lipoprotein cholesterol reduction has proved to be highly effective in reducing the risk of major cardiovascular (CV) events in ...
Rimjhim Sahu, Sahu, Rimjhim, Rekha Mehani, V. K. Yadav, Yadav, V. K., Shukla, Ajay, Mehani, Rekha, Ajay Shukla   +7 more
core   +1 more source